Effect of lovastatin on lipoprotein fluidity in patients with hypercholesterolaemia.
Lovastatin was administered to six hypercholesterolaemic patients (mean plasma cholesterol 450 mg dl-1). Plasma lipoproteins (VLDL, LDL, and HDL) were separated before and following 7 and 12 weeks treatment with lovastatin. Fluidity was quantified by fluorescence polarization measurements using 1,6-diphenyl 1,3,5 hexatriene (DPH) as the fluorescent probe. Lovastatin treatment resulted in a significant reduction of total plasma cholesterol, LDL cholesterol and VLDL cholesterol (-41%, -44%, -68%, respectively). Fluidity measurements showed significant (p < 0.01) increase in LDL fluidity by 11% and 21% after 7 and 12 weeks of lovastatin treatment, whereas, VLDL fluidity was increased by 27% after 12 weeks of therapy. HDL fluidity was not altered. These alterations in the fluidity of the atherogenic lipoproteins (LDL and VLDL) in hypercholesterolaemic patients may prove to be of significance in reducing the risk of atherosclerosis.
Levy
Y
Y
Lipid Research Unit, Rambam Medical Center, Haifa, Israel.
Klein
L
L
Aviram
M
M
Brook
G J
GJ
Cogan
U
U
D000328:Adult; D000368:Aged; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000737:chemistry; D008078:Cholesterol, LDL / Q000097:blood / Q000737:chemistry; D015243:Cholesterol, VLDL / Q000097:blood / Q000737:chemistry; D004161:Diphenylhexatriene; D005260:Female; D005454:Fluorescence Polarization; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy; D008074:Lipoproteins / Q000097:blood* / Q000737:chemistry*; D008148:Lovastatin / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013696:Temperature
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D008074:Lipoproteins; D004161:Diphenylhexatriene; D002784:Cholesterol; D008148:Lovastatin